On April 13, 2023 Sysmex Inostics Inc., a subsidiary of Japan’s Sysmex Corporation and Baltimore-based biotechnology firm, and Genomic Testing Cooperative (GTC), based in Irvine, California, reported to have formed a strategic partnership for Sysmex Inostics to commercialize GTC’s tissue and liquid biopsy solid tumors and hematology assay services to biopharma customers (Press release, Sysmex Inostics, APR 13, 2023, View Source [SID1234630047]). This includes GTC’s Solid Tumor Profile Plus, Liquid Trace Solid Tumor Profile, Liquid Trace Hematology Profile, and Hematology Profile Plus assay services.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The partnership synergizes GTC’s proprietary genomic databases, technology in artificial intelligence (AI), and DNA and RNA next generation sequencing (NGS) profiling, with Sysmex Inostics’ global commercial capabilities in biopharma therapeutic development and ultra-sensitive Plasma-Safe-SeqS technology.
Shinichi Sato, president, and Chief Executive Officer of Sysmex Inostics, stated, "Our new relationship with GTC extends our commitment to our biopharma partners. We understand not one testing solution fits all stages of therapeutic development and it was imperative to offer our biopharma partners GTC’s broader panels for their discovery work." And added, "It’s truly a special day for Sysmex Inostics."
"The alliance with Sysmex Inostics is fundamental to our mission of democratizing genomic testing and making it available and affordable to every patient dealing with cancer. It represents another step forward in our efforts to expand our cooperative model," stated Maher Albitar, MD, Founder, Chief Executive Officer, and Chief Medical Officer of GTC.
The collaboration provides biopharma a full suite of assay services from both companies for each phase in the clinical trial process. The companies will also work jointly on improvements and new indications of the tests for use by biopharma researchers.
GTC’s cooperative state-of the-art and cost-effective offerings are distinctive and cover various modalities including chromosomal abnormalities, RNA expression and immunophenotyping, tumor cell of origin, homologous recombination deficiency (HRD), tumor mutation burden (TMB), exon skipping, and levels of EBV and HPV viral RNA if present. GTC testing uses proprietary AI analysis of DNA and RNA data from blood and tissue samples. Further setting them apart, various GTC’s tests have CE IVDR and New York State (NYS) approval with Medicare Reimbursement, the lab has CAP, CLIA and NYS licensure.
Sysmex Inostics adds its long-standing biopharma relationships and commercial capabilities to the partnership. The company will also continue to serve the market with CLIA-validated Plasma-Safe-SeqS testing, expertly curated and ultra-sensitive liquid biopsy panel to detect known cancer driving mutations. The technology allows biopharma to expedite clinical trial patient enrollment with the peace of mind their patients are being monitored with one of the most sensitive liquid biopsy tests on the market.
Sysmex Inostics & GTC will exhibit at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2023 in Orlando, FL from April 16, through April 19, 2023. Both companies will take meetings with the over 20,000 global cancer research professionals in attendance.